The Pancreas Cancer Microenvironment

被引:1118
作者
Feig, Christine [1 ]
Gopinathan, Aarthi [1 ]
Neesse, Albrecht [1 ]
Chan, Derek S. [1 ]
Cook, Natalie [1 ,2 ]
Tuveson, David A. [1 ,2 ,3 ]
机构
[1] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Dept Oncol, Cambridge, England
[3] Lustgarten Fdn Pancreat Canc Lab Cold Spring Harb, Cold Spring Harbor, NY USA
关键词
PHASE-III TRIAL; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTORS; SECRETING TUMOR VACCINE; STELLATE-CELLS; DUCTAL ADENOCARCINOMA; CLINICAL-TRIALS; STEM-CELLS; PROGNOSTIC-SIGNIFICANCE; IMMUNE ACTIVATION;
D O I
10.1158/1078-0432.CCR-11-3114
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,000 deaths per year worldwide. Despite extensive efforts, cytotoxic and targeted therapies have provided only limited efficacy for patients with PDA to date. One contributing factor to the failure of systemic therapies may be the abundant tumor stromal content that is the characteristic of PDA. The PDA stroma, aptly termed the tumor microenvironment, occupies the majority of the tumor mass, and consists of a dynamic assortment of extracellular matrix components and nonneoplastic cells including fibroblastic, vascular, and immune cells. Recent work has revealed that the PDA stroma supports tumor growth and promotes metastasis and simultaneously serves as a physical barrier to drug delivery. Accordingly, methods that alter stromal composition or function, for instance interference with the vasculature via Notch/Hedgehog pathway inhibition or relief of vascular compression by hyaluronidase, are under active investigation. Here, we will review our current understanding of the PDA tumor microenvironment, and highlight opportunities for further exploration that may benefit patients. Clin Cancer Res; 18(16); 4266-76. (C) 2012 AACR.
引用
收藏
页码:4266 / 4276
页数:11
相关论文
共 104 条
[1]
Transcriptional network governing the angiogenic, switch in human pancreatic cancer [J].
Abdollahi, Amir ;
Schwager, Christian ;
Kleeff, Joerg ;
Esposito, Irene ;
Domhan, Sophie ;
Peschke, Peter ;
Hauser, Kai ;
Hahnfeldt, Philip ;
Hlatky, Lynn ;
Debus, Juergen ;
Peters, Jeffrey M. ;
Friess, Helmut ;
Folkman, Judah ;
Huber, Peter E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) :12890-12895
[2]
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma [J].
Aguirre, AJ ;
Bardeesy, N ;
Sinha, M ;
Lopez, L ;
Tuveson, DA ;
Horner, J ;
Redston, MS ;
DePinho, RA .
GENES & DEVELOPMENT, 2003, 17 (24) :3112-3126
[3]
MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].
ALMOGUERA, C ;
SHIBATA, D ;
FORRESTER, K ;
MARTIN, J ;
ARNHEIM, N ;
PERUCHO, M .
CELL, 1988, 53 (04) :549-554
[4]
Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture [J].
Apte, MV ;
Haber, PS ;
Applegate, TL ;
Norton, ID ;
McCaughan, GW ;
Korsten, MA ;
Pirola, RC ;
Wilson, JS .
GUT, 1998, 43 (01) :128-133
[5]
Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma [J].
Astsaturov, Igor A. ;
Meropol, Neal J. ;
Alpaugh, R. Katherine ;
Burtness, Barbara A. ;
Cheng, Jonathan D. ;
McLaughlin, Sue ;
Rogatko, Andre ;
Xu, Zhiheng ;
Watson, James C. ;
Weiner, Louis M. ;
Cohen, Steven J. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (01) :70-75
[6]
Identification, culture, and characterization of pancreatic stellate cells in rats and humans [J].
Bachem, MG ;
Schneider, E ;
Gross, H ;
Weidenbach, H ;
Schmid, RM ;
Menke, A ;
Siech, M ;
Beger, H ;
Grünert, A ;
Adler, G .
GASTROENTEROLOGY, 1998, 115 (02) :421-432
[7]
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer [J].
Bailey, Jennifer M. ;
Swanson, Benjamin J. ;
Hamada, Tomofumi ;
Eggers, John P. ;
Singh, Pankaj K. ;
Caffery, Thomas ;
Ouellette, Michel M. ;
Hollingsworth, Michael A. .
CLINICAL CANCER RESEARCH, 2008, 14 (19) :5995-6004
[8]
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].
Beatty, Gregory L. ;
Chiorean, Elena G. ;
Fishman, Matthew P. ;
Saboury, Babak ;
Teitelbaum, Ursina R. ;
Sun, Weijing ;
Huhn, Richard D. ;
Song, Wenru ;
Li, Dongguang ;
Sharp, Leslie L. ;
Torigian, Drew A. ;
O'Dwyer, Peter J. ;
Vonderheide, Robert H. .
SCIENCE, 2011, 331 (6024) :1612-1616
[9]
HIF at a glance [J].
Brahimi-Horn, M. Christiane ;
Pouyssegur, Jacques .
JOURNAL OF CELL SCIENCE, 2009, 122 (08) :1055-1057
[10]
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].
Bramhall, SR ;
Schulz, J ;
Nemunaitis, J ;
Brown, PD ;
Baillet, M ;
Buckels, JAC .
BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167